A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy. ...
检索时限起始于1990年1月,截至2023年8月,英文文献检索词主要包括BRCA1/2、hereditary breast cancer、hereditary ovarian cancer、germline mutation、screening test、population screening、BRCAscreening、cancer risk assessment、cancer susceptib...
[2]Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112 [3]Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA...
Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU Case Rep. 2024 Aug 4;7(5):395-...
Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697-1701. DOI: 10.1038/bjc.2012.146 Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic ...
3.1. Prostate cancer In total, 16 of 376 BRCA1 and 26 of 447 BRCA2 mutation carriers were diagnosed with PCa during median follow-up of 5.9 and 5.3 yr, respectively (Table 1). All PCa diagnoses were confirmed via either registry linkage or the participating clinics. Table 1. Particip...
Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU Case Rep. 2024 Aug 4;7(5):395-...
[5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. doi:10.1093/jnci/91.15.1310 [6]Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA...
“While the detection of a BRCA mutation on this test does indicate an increased risk, only a small percentage of Americans carry one of these three mutations and most BRCA mutations that increase an individual’s risk are not detected by this test. The test should not be used as a ...
mutation testing based on next generation sequencing technology. To further standardize the workflow forBRCAgermline mutation screening in the Chinese population, a consensus development group was established by the China Anti-Cancer Association Tumor Biomarker Professional Committee and the Shanghai Anti-...